BAYER AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.06 EUR | +0.03% |
|
-0.11% | -22.41% |
| 11:34am | Bayer: new positive data for Nubeqa | CF |
| 10:44am | Bayer with trial success in prostate cancer - Analyst: As expected | DP |
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows:
- agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.;
- pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.;
- OTC products and nutritional supplements (12.7%);
- other (0.5%).
Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
26.06
EUR
Average target price
35.91
EUR
Spread / Average Target
+37.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.41% | 27.86B | |
| +61.53% | 848B | |
| +33.58% | 627B | |
| -3.66% | 363B | |
| +15.06% | 318B | |
| +9.18% | 299B | |
| +12.02% | 234B | |
| +16.19% | 225B | |
| +15.67% | 179B | |
| +2.47% | 167B |
- Stock Market
- Equities
- BAYN Stock
- News Bayer AG
- Bayer's Prostate Cancer Combo Extends Progression-Free Survival in Late-stage Trial
